Fortress Biotech Inc   (FBIO)
Other Ticker:  
Price: $2.4300 $0.35 16.827%
Day's High: $2.44 Week Perf: 31.35 %
Day's Low: $ 2.07 30 Day Perf: 19.12 %
Volume (M): 591 52 Wk High: $ 12.75
Volume (M$): $ 1,436 52 Wk Avg: $6.08
Open: $2.12 52 Wk Low: $0.30

 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) 81
 Net Income (TTM) (Millions $) -183
 Cash Flow (TTM) (Millions $) -136
 Capital Exp. (TTM) (Millions $) 5

Fortress Biotech Inc
Fortress Biotech Inc is a biopharmaceutical company based in the United States that focuses on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. The company operates through multiple subsidiary companies, each specializing in a different therapeutic area such as oncology, rare diseases, and gene therapy. Fortress Biotech's unique model allows it to leverage the expertise of its subsidiary companies while providing them with the necessary resources for research, development, and commercialization. By partnering with leading academic institutions and strategic partners, Fortress Biotech aims to bring novel and promising therapies to patients in need.

   Company Address: 1111 Kane Concourse Suite 301 Bay Harbor Islands 33154 FL
   Company Phone Number: 652-4500   Stock Exchange / Ticker: NASDAQ FBIO
   FBIO is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Fortress Biotech Secures Promising Future for Shareholders with Successful Completion of Registered Direct Offering

Published Wed, Jan 3 2024 9:02 PM UTC

Fortress Biotech Successfully Completes Registered Direct Offering, Securing Promising Future for Shareholders
MIAMI, Jan. 03, 2024 - Fortress Biotech, Inc. (Nasdaq: FBIO), a renowned biopharmaceutical company known for its efficient acquisition, development, and commercialization of therapeutic products, has recently made a significant stride. In today's press release, ...

Financing Agreement

Fortress Biotech's Strategic Financing Fuels Growth Momentum Amid Impressive Financial Update

Published Fri, Dec 29 2023 1:21 PM UTC

Fortress Biotech, an innovative biopharmaceutical company dedicated to acquiring, developing, and commercializing promising therapeutic products and candidates, recently unveiled a groundbreaking definitive agreement for an issuance and sale of its common stock and accompanying warrants. The move is aimed at further strengthening its product pipeline, enhancing res...

Fortress Biotech Inc

Breakthrough Financial Success: Fortress Biotech Inc Soars with Revenue Surge and Improved EPS

Fortress Biotech Inc Reports Improved Financial Performance and Revenue Surge
Fortress Biotech Inc, a major player in the pharmaceutical preparations industry, has announced its fiscal results for the period ending September 30, 2023. The company reported a decrease in loss per share, revenue surge, and improved EPS compared to the previous reporting period.
In terms of earnings per share (EPS), Fortress Biotech Inc recorded a loss of $-0.94 per share for the fiscal year ending September 30, 2023. This represents a significant improvement when compared to the loss of $-3.75 per share reported in the same period a year prior. Furthermore, EPS improved from $-3.60 per share in the previous reporting period.

Fortress Biotech Inc

Fortress Biotech Inc Faces Struggles as Revenue Plummets by 7.942% in Q2 2023

Fortress Biotech Inc, a prominent player in the biotechnology industry, experienced a significant decline in revenue and net deficit during the April to June 30, 2023 fiscal period. This article sheds light on the unexpected turn of events and the potential factors contributing to the company's financial struggles. Additionally, we explore some interesting facts about Fortress Biotech Inc's performance and discuss the impact of slowing demand on various financial indicators.
Revenue Decline and Increasing Deficit
During the mentioned fiscal period, Fortress Biotech Inc witnessed a sharp decline in revenue, which dropped by 7.942% year-on-year to $17.39 million. This decrease in revenue can be attributed to lower demand for the company's products or services. As a result, the company recorded a net deficit of $-59.301 million, marking an increase from the previous year's $-53.930 million.

Fortress Biotech Inc

Fortress Biotech Inc's Bleak Financial Results Raise Concerns among Shareholders

The recent financial results announced by Fortress Biotech Inc have painted a bleak picture of the company's future prospects, causing significant concern for its shareholders. For the fiscal period ending March 31, 2023, the company reported losses of $0.21 per share, which is a worrying increase compared to the $0.18 loss per share reported the previous year.
While the company did manage to improve its EPS from the previous quarter, this cannot be viewed as a clear positive sign, given the extent of the losses suffered by the company. Furthermore, even the incremental improvement in EPS is not enough to offset the significant decline in revenue that the company experienced.


Fortress Biotech Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com